The Goldman Sachs Group Initiates Coverage on Silence Therapeutics (NASDAQ:SLN)

Research analysts at The Goldman Sachs Group began coverage on shares of Silence Therapeutics (NASDAQ:SLN - Get Free Report) in a research report issued on Tuesday, Marketbeat Ratings reports. The firm set a "sell" rating and a $6.00 price target on the stock. The Goldman Sachs Group's price objective suggests a potential upside of 24.35% from the stock's previous close.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, January 29th. BMO Capital Markets reiterated an "outperform" rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. William Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Chardan Capital restated a "buy" rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $45.00.

Silence Therapeutics Stock Up 7.2 %

Shares of Silence Therapeutics stock traded up $0.33 on Tuesday, reaching $4.83. The stock had a trading volume of 444,596 shares, compared to its average volume of 355,263. The company has a 50 day moving average price of $6.10 and a 200 day moving average price of $12.84. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72. The stock has a market capitalization of $144.41 million, a P/E ratio of -3.07 and a beta of 1.05.

Institutional Investors Weigh In On Silence Therapeutics

A number of large investors have recently modified their holdings of the business. Barclays PLC grew its holdings in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Silence Therapeutics during the third quarter worth about $56,000. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics during the fourth quarter worth about $26,000. Y Intercept Hong Kong Ltd lifted its position in shares of Silence Therapeutics by 22.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company's stock worth $383,000 after purchasing an additional 3,923 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after acquiring an additional 5,233 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.